Thiethylperazine; clinical antipsychotic efficacy and correlation with potency in predictive systems

Area of Science:

• Pharmacology
• Neuroscience
• Psychiatry

Background:

• The dopamine hypothesis of neuroleptic action posits a direct correlation between clinical antipsychotic potency and dopaminergic antagonism.
• Thiethylperazine maleate, a phenothiazine antiemetic, exhibits dopaminergic antagonism but is not traditionally considered a clinical neuroleptic.

Purpose of the Study:

• To investigate the potential neuroleptic activity of thiethylperazine maleate.
• To evaluate the dopaminergic antagonism and clinical efficacy of thiethylperazine maleate in comparison to chlorpromazine.

Main Methods:

• Assessed dopaminergic antagonism through measurement of cerebrospinal fluid homovanillic acid in monkeys, striatal dihydroxyphenylacetic acid in rats, and prolactin levels in humans.
• Conducted a clinical trial to assess the neuroleptic efficacy of thiethylperazine maleate in schizophrenic patients.

Main Results:

• Thiethylperazine maleate demonstrated significant dopaminergic antagonism across all tested neurochemical and neuroendocrine systems.
• In clinical trials, thiethylperazine maleate exhibited full neuroleptic activity, showing approximately three times the potency of chlorpromazine.
• Observed differences in efficacy compared to previous studies are attributable to variations in dosage.

Conclusions:

• Thiethylperazine maleate possesses significant antipsychotic properties, challenging its prior classification solely as an antiemetic.
• The study supports the dopamine hypothesis by demonstrating a strong link between dopaminergic antagonism and clinical antipsychotic efficacy for thiethylperazine maleate.
• Dosage is a critical factor influencing the observed clinical efficacy of thiethylperazine maleate.